SRJR Lifesciences LLP has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SRJR Lifesciences LLP, the promoter of Bafna Pharmaceuticals Limited, has filed a disclosure under SEBI Regulation 31(4) confirming that they have not created any encumbrance (pledge) over their shareholding in the company during the financial year ended March 31, 2026. This is a routine annual compliance filing required from promoters of listed companies. The disclosure was submitted to both BSE and NSE on April 1, 2026. The company's ticker is BAFNAPH with security code 532989 on BSE.
This is a positive signal for existing shareholders as it confirms that the promoter's stake in the company is not pledged or encumbered, reducing risk of potential stake dilution or forced selling.